MOLECULAR PATHOGENESIS OF MIXED LINEAGE LEUKAEMIA
Grant number: 1144649 | Funding period: 2019 - 2021
Chromosomal translocations in the MLL gene results in aggressive leukaemias. Several drugs developed to target proteins that interact with the MLL fusion proteins are now being tested in the clinic. Despite this progress, our understanding of how the MLL fusion proteins cause leukaemia remains incomplete. In particular, it is unclear how the MLL fusion protein drives the development of leukaemia. In this project I will address these important issues with cell and molecular biology methods.
Related publications (1)
Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation
Omer Gilan, Inmaculada Rioja, Kathy Knezevic, Matthew J Bell, Miriam M Yeung, Nicola R Harker, Enid YN Lam, Chun-wa Chung, Paul Bamborough, Massimo Petretich, Marjeta Urh, Stephen J Atkinson, Anna K Bassil, Emma J Roberts, Dane Vassiliadis, Marian L Burr, Alex GS Preston, Christopher Wellaway, Thilo Werner, James R Gray
The two tandem bromodomains of the BET (bromodomain and extraterminal domain) proteins enable chromatin binding to facilitate tran..